Article
Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
Clinical lung cancer - 1 Nov 2011
Asami Kazuhiro, Koizumi Tomonobu, Hirai Kazuya, Ameshima Shingo, Tsukadaira Akihiro, Morozumi Nobutoshi, Morikawa Akio, Atagi Shinji, Kawahara Masaaki
Abstract excerpt
UNLABELLED: Efficacy of first-line gefitinib for elderly epidermal growth factor receptor mutated patients with lung adenocarcinoma is uncertain. This study was aimed to investigate efficacy of gefitinib for such population. The primary endpoint was response rate (RR) and at least 12 cases were needed. Overall RR was 59% (95% confidence interval, 33%-81%) and first-line gefitinib was effective for elderly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.